Healthcare provider profile · identity verified

Glendon P Rougeou, MD

Allopathic & Osteopathic Physicians|Family Medicine · SAN FRANCISCO, CA · NPI 1992719371

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Glendon P Rougeou, MD received $14.50 in general payments during 2025 across 1 reported records.

Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Rybelsus by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$14.50

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$14.50	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$14.50	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Payment records were found, but the reported records did not identify a specific associated product for this analysis.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	145	34
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Rybelsus open payments reported associated product	CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076	Rybelsus · 2024 Exact normalized brand match · 1 Part D row	55	12

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	598	205
Amlodipine Besylate	Amlodipine Besylate	550	174
Lisinopril	Lisinopril	508	168
Levothyroxine Sodium	Levothyroxine Sodium	454	140
Losartan Potassium	Losartan Potassium	392	118
Omeprazole	Omeprazole	310	108
Rosuvastatin Calcium	Rosuvastatin Calcium	289	98
Gabapentin	Gabapentin	256	80
Hydrochlorothiazide	Hydrochlorothiazide	256	82
Metoprolol Succinate	Metoprolol Succinate	247	86
Tamsulosin Hcl	Tamsulosin Hcl	186	64
Metformin Hcl	Metformin Hcl	180	65
Montelukast Sodium	Montelukast Sodium	169	52
Pantoprazole Sodium	Pantoprazole Sodium	158	61
Furosemide	Furosemide	153	50
Metoprolol Tartrate	Metoprolol Tartrate	148	53
Eliquis	Apixaban	145	30
Ozempic	Semaglutide	145	34
Pravastatin Sodium	Pravastatin Sodium	118	41
Metformin Hcl Er	Metformin Hcl	117	34
Simvastatin	Simvastatin	107	39
Albuterol Sulfate Hfa	Albuterol Sulfate	103	42
Allopurinol	Allopurinol	103	30
Tramadol Hcl	Tramadol Hcl	102	26
Clopidogrel	Clopidogrel Bisulfate	98	36
Famotidine	Famotidine	97	32
Chlorthalidone	Chlorthalidone	96	27
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	90	18
Lorazepam	Lorazepam	87	23
Carvedilol	Carvedilol	84	25
Enalapril Maleate	Enalapril Maleate	83	32
Citalopram Hbr	Citalopram Hydrobromide	82	24
Fluticasone Propionate	Fluticasone Propionate	81	38
Escitalopram Oxalate	Escitalopram Oxalate	79	26
Alprazolam	Alprazolam	78	24
Meloxicam	Meloxicam	77	29
Duloxetine Hcl	Duloxetine Hcl	75	19
Isosorbide Mononitrate Er	Isosorbide Mononitrate	71	16
Potassium Chloride	Potassium Chloride	68	27
Finasteride	Finasteride	67	23
Glipizide	Glipizide	65	19
Methylprednisolone	Methylprednisolone	64	60
Atenolol	Atenolol	62	20
Buspirone Hcl	Buspirone Hcl	62	15
Jardiance	Empagliflozin	60	18
Sertraline Hcl	Sertraline Hcl	59	22
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	57	52
Glimepiride	Glimepiride	57	20
Tresiba Flextouch U-200	Insulin Degludec	56	suppressed
Rybelsus	Semaglutide	55	12
Mounjaro	Tirzepatide	53	suppressed
Ropinirole Hcl	Ropinirole Hcl	53	14
Glipizide Er	Glipizide	51	22
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	51	18
Triamcinolone Acetonide	Triamcinolone Acetonide	50	33
Myrbetriq	Mirabegron	49	12
Paroxetine Hcl	Paroxetine Hcl	48	15
Trazodone Hcl	Trazodone Hcl	47	20
Hydralazine Hcl	Hydralazine Hcl	46	14
Zolpidem Tartrate	Zolpidem Tartrate	46	15
Ezetimibe	Ezetimibe	41	13
Fluoxetine Hcl	Fluoxetine Hcl	40	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	39	15
Meclizine Hcl	Meclizine Hcl	38	11
Celecoxib	Celecoxib	37	15
Clonazepam	Clonazepam	37	12
Pregabalin	Pregabalin	37	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	35	32
Linzess	Linaclotide	35	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	35	16
Warfarin Sodium	Warfarin Sodium	35	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	33	14
Lovastatin	Lovastatin	33	11
Benazepril Hcl	Benazepril Hcl	32	suppressed
Prednisone	Prednisone	31	28
Xarelto	Rivaroxaban	30	suppressed
Primidone	Primidone	29	12
Trulicity	Dulaglutide	29	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	28	14
Bupropion Hcl	Bupropion Hcl	27	suppressed
Mirtazapine	Mirtazapine	27	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	14
Vitamin D2	Ergocalciferol (Vitamin D2)	26	suppressed
Alendronate Sodium	Alendronate Sodium	25	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Ipratropium Bromide	Ipratropium Bromide	25	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	24	suppressed
Synthroid	Levothyroxine Sodium	24	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Vascepa	Icosapent Ethyl	23	suppressed
Clonidine Hcl	Clonidine Hcl	22	suppressed
Diclofenac Sodium	Diclofenac Sodium	22	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Labetalol Hcl	Labetalol Hcl	22	suppressed
Nitroglycerin	Nitroglycerin	22	suppressed
Propranolol Hcl	Propranolol Hcl	22	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	21	suppressed
Memantine Hcl	Memantine Hcl	20	suppressed
Ventolin Hfa	Albuterol Sulfate	20	11
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Ibuprofen	Ibuprofen	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Breo Ellipta	Fluticasone/Vilanterol	18	suppressed
Nystatin	Nystatin	18	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Fenofibrate	Fenofibrate	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Ondansetron Hcl	Ondansetron Hcl	17	suppressed
Fluconazole	Fluconazole	16	12
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	15	suppressed
Gemfibrozil	Gemfibrozil	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	14	suppressed
Niacin Er	Niacin	14	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Febuxostat	Febuxostat	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Topiramate	Topiramate	13	suppressed
Baclofen	Baclofen	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Midodrine Hcl	Midodrine Hcl	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Temazepam	Temazepam	12	suppressed
Cephalexin	Cephalexin	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Divalproex Sodium	Divalproex Sodium	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$14.50 · 1 records	Novo Nordisk Inc	—	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error